# Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer

> **NCT00331552** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Washington** · enrollment: 30 (actual)

## Conditions studied

- HER2-positive Breast Cancer
- Male Breast Cancer
- Recurrent Breast Cancer
- Stage IV Breast Cancer

## Interventions

- **DRUG:** pegylated liposomal doxorubicin hydrochloride
- **DRUG:** cyclophosphamide
- **BIOLOGICAL:** trastuzumab

## Key facts

- **NCT ID:** NCT00331552
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** 2011-02
- **Final completion:** 2012-02
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2017-07-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00331552

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00331552, "Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00331552. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*